Short answer
Tenaya Therapeutics Inc (TNYA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Tenaya’s earnings release covers the quarter ended June 30, 2026.
Tenaya Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Tenaya’s earnings release covers the quarter ended June 30, 2026
- Exhibit 99.1 contains the company’s financial results and management commentary
- Investor focus: cash runway, clinical-program spending and development updates in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $43.4M, or $0.20 per share, including a $21.8M non-cash GMMC lease impairment
- Cash $78.1M, funding planned operations through Q3 2027 and reducing near-term financing pressure
- TN-201 data: all six evaluable patients improved hypertrophy or symptom measures, with no dose-limiting toxicities
- TN-401 data: PVC counts declined a mean 64% from baseline, with no dose-limiting toxicities
- Catalysts in Q4 2026: additional TN-201 and TN-401 data plus regulatory updates on pivotal trial plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tenaya Therapeutics Inc 8-K filings
Get the next TNYA 8-K as it lands
Follow TNYA for push alerts, or ask the research agent what this filing means.